Modification of phage for increased antibacterial effect towards dental biofilm

I ntroduction of new genetic engineering techniques has enabled a more precise modification of bacteriophage genomes in basic science and engineering. Pires et al. (1), in a review paper, discuss advances in genetically engineered phages over the last decade. The present commentary focuses on the aspect of modification of phage for enhanced antibacterial activity in dental biofilms. Biofilms consist of bacteria transferred from a freeswimming (planktonic state) to a multitude of bacterial cells encased in a self-produced polysaccharide matrix of hydrated extracellular polymeric substances (2). Their structure is complex being filled with pillar-formed mature macrocolonies surrounded by fluid-filled channels (3). These structured microbial communities are characterized by reduced metabolic activity, particularly in the inner layers. Another important feature is their association with chronic infections such as Pseudomonas aeruginosa infection in cystic fibrosis, Staphylococcus epidermidis and S. aureus infections, urinary tract infection, periodontal disease, and root canal infection. It is well known that biofilm infections can be difficult to eradicate with antimicrobials. Thus, a 100to 1,000-fold increase in antimicrobial tolerance to biofilms compared to planktonic cells has been reported (4). This effect is often related to the biofilm matrix that can limit diffusion of molecules and particles, or to reduced bacterial metabolism (3, 5, 6). After their discovery in the early 20th century, bacteriophages were considered to have a great potential as antibacterial agents. Due to poorly controlled clinical trials and inconsistent results, this potential has still to be realized (1). The discovery of penicillin in 1928 and the arrival of the antibiotic era also reduced the interest for phage therapy, at least in the West, while its use continued in Eastern Europe and the former Soviet Union (7). In recent years, the increase in multidrug-resistant bacteria has renewed the interest for using phages as antimicrobial agents, recently also in the oral cavity (8). Gene engineering has made it possible to modify these bacterial viruses so that they can precisely control and detect bacteria and serve as new sources of antibacterials (1). They are also being developed as vehicles for drug delivery and vaccines and for assembly of new materials. To increase the efficiency of phage therapy against biofilms, Lu and Collins (9) engineered a T7 phage to express the biofilm-degrading enzyme dispersin B (DspB). Interestingly, the dsB gene from Aggregatibacter actinomycetemcomitans was cloned downstream of the T7select415-1 10B capsid gene under the control of the T78 10 promoter. The phage created was efficient against Escherichia coli TG1 biofilms and reduced biofilm cell counts by 4.5 orders after treatment for 24 h. This reduction was 2 orders of magnitude more than that achieved by the wild-type nonenzymatic phage. In future work, this technology might involve other enzymes that could target the heterogeneous extracellular composition of dental biofilms to improve their eradication. Also, the T7 phage has been engineered to encode an enzymatic interference with quorum sensing (10). This is a bacterial cell cell communication system involved in biofilm formation (11, 12). Here, the engineered phage T7aiiAwas created by cloning the acyl-homoserine lactone lactonase (AHL-lactonase) gene aiiA from Bacillus anthracis into the T7select415-1 phage vector (9, 10). The quorum-quenching enzyme inactivates acyl-homoserine lactone (AHL), which is a quorum-sensing molecule, by hydrolyzing its lactone bonds (13). In order to test the effect of quorum-sensing phage T7aiiA on biofilm formation, E. coli and P. aeruginosa were mixed together to form biofilms in the presence of the engineered or wildtype phage for 4 and 8 h (10). Interestingly, phage T7aiiA ournal of ral icrobiology